Empowering Precision Diagnostics
Bringing ImmunoGuide ELISA technologies to Europe and beyond
Validated ELISA kits for therapeutic drug monitoring and anti-drug antibody detection, for clinical labs, research institutions, and biotech teams. For Research Use Only.

Featured ELISA kits
Drug-level and anti-drug antibody assays across TNF-alpha, VEGF, EGFR, HER2, and more.
ADALIMUMAB ELISA
Analyte: Adalimumab
View kitADALIMUMAB ELISA (MAB-BASED)
Analyte: Adalimumab
View kitAFLIBERCEPT ELISA
Analyte: Aflibercept
View kitANTIBODY TO ADALIMUMAB ELISA
Analyte: Adalimumab
View kitANTIBODY TO BEVACIZUMAB ELISA
Analyte: Bevacizumab
View kitANTIBODY TO CERTOLIZUMAB PEGOL ELISA
Analyte: Certolizumab Pegol
View kitFrom our journal
Background on ELISA methods, therapeutic drug monitoring, anti-drug antibodies, and assay validation.
One Platform, All Analytes: Why Microvolume Whole Blood Is Reframing Immunosuppressant TDM
Conventional immunosuppressant TDM splits calcineurin inhibitors and mycophenolic acid across two matrices, two workflows, and two pretreatment pipelines. A 2026 integrated analytical framework published in Bioanalysis, supported by recent LC-MS/MS validation studies using 2.8 µL fingerstick whole blood, challenges that assumption directly. This article reviews the analytical evidence, the hematocrit correction requirement, and what the framework means for assay scientists building fit-for-purpose microvolume methods.
When ADA Titer Is Not Enough: Rethinking the Gate to Neutralizing Antibody Testing
A series of papers published in Bioanalysis throughout 2026 argues that titer-gated neutralizing antibody testing can miss clinically relevant neutralization while generating incidence numbers that mislead development teams. The papers converge on signal-to-noise ratio from the screening tier as a continuous, biologically richer alternative to discretized titer scores, and call for NAb assay sensitivity to be matched to molecule-specific clinical endpoints rather than population-average tier thresholds.
Multiplex Luminex Assay Enables Simultaneous Domain-Specific ADA Detection for Multidomain Biotherapeutics
Standard bridging immunogenicity assays cannot distinguish which domain of a multidomain biotherapeutic is driving an anti-drug antibody response. A Luminex bead-based multiplex approach published in Bioanalysis in November 2026 addresses this gap by enabling simultaneous, domain-resolved ADA detection within a single assay well, with sub-100 ng/mL sensitivity and no prozone effects up to 20,000 ng/mL. This article reviews the method, its validation considerations, and what it means for scientists building immunogenicity programs for bispecific antibodies and other multidomain drugs.